Carcinoid Tumors Clinical Trial
Official title:
A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS
Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.
With the exception of surgery for localized disease, there is presently a lack of available
therapies with proven survival benefit for patients with neuroendocrine tumors (NET).
Available treatment options for unresectable disease include the use of somatostatin
analogs, which may relieve symptoms related to hormonal hypersecretion. The efficacy of
cytotoxic chemotherapy in patients with metastatic carcinoid tumors is also limited.
Combinations of either streptozocin and cyclophosphamide, or streptozocin and
5-fluorouracil, appear to be inactive, and both regimens are associated with substantial
toxicity.
Receptor tyrosine kinases (RTKs) are implicated in deregulated/ autocrine proliferation and
survival of solid and hematologic cancer cells. Sunitinib malate is an orally administered
small molecule that inhibits the tyrosine kinase enzymatic activities of the receptors for
VEGF and PDGF, and also blocks signalling through the KIT, FLT3 and RET pathways.
Therefore, sunitinib malate may provide an opportunity for a novel therapeutic strategy for
the treatment of subjects with NET.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00580320 -
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
|
Phase 1 | |
| Completed |
NCT02575300 -
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02441088 -
Theranostics: 68GaDOTATOC and 90YDOTATOC
|
Phase 2 | |
| Terminated |
NCT00227136 -
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
|
Phase 3 | |
| Terminated |
NCT00947167 -
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
|
Phase 2 | |
| Terminated |
NCT02177773 -
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02795858 -
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
|
Phase 2 | |
| Terminated |
NCT02859064 -
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
|
Phase 2 | |
| Completed |
NCT00088595 -
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
|
Phase 2 | |
| Completed |
NCT01619865 -
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01253161 -
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
|
Phase 2 | |
| Terminated |
NCT02359500 -
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
|
Phase 1 | |
| Not yet recruiting |
NCT01373736 -
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
|
Phase 3 | |
| No longer available |
NCT01980732 -
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
|
N/A |